Previous 10 | Next 10 |
Urovant Sciences (UROV +93% as Sumitovant Biopharma to acquire balance shares for $16.25/share.CBAK Energy Technology (CBAT) +55%.Hall of Fame Resort & Entertainment (HOFV +37% after providing update on the Inaugural NFL Alumni Academy.Li Auto (LI +29% o...
Cyclerion Therapeutics (CYCN): Q3 net loss of $18.8MCash, cash equivalents, and restricted cash of $71M.Press Release For further details see: Cyclerion Therapeutics reports Q3 results
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases Company revamping its organization to focus on critical IW-6463 ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks limped into the close Friday to finish at session lows, with defensive names including health care and utilities moving just enough to keep the S&am...
Gainers: Staffing 360 Solutions (STAF) +86%.China HGS Real Estate (HGSH) +65%.Huttig Building Products (HBP) +39%.Dragon Victory International (LYL) +35%.SPI Energy (SPI) +30%.Organogenesis (ORGO) +20%.Armata Pharmaceuticals (ARMP) +20%.Cars.com (CARS) +18%.Precigen (PGEN) +17%...
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cycl...
Shares of clinical-stage biotech Cyclerion Therapeutics (NASDAQ: CYCN) are down by an eye-popping 48% as of noon EDT Wednesday. The small-cap biotech's stock is crashing in response to a negative midstage trial result for its sickle cell disease candidate olinciguat. Cyclerion d...
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...
After announcing encouraging data from IW-6463 CNS translational pharmacology study, Cyclerion Therapeutics tanked ([[CYCN]] -48.0%) after it said that top-line results from its Phase 2 study of olinciguat, did not demonstrate adequate activity to support further internal clinical d...
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
Cyclerion Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is one of today's top gainers. The company's shares have moved 37.28% on the day to $2.81. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serio...